Home New Customer? Create Account
Member Login:

Blasticidin Selection Plasmids

OG386 - pSF-CMV-FMDV-Blast

PRICE

Starting at: $307.00

Please Choose:

Shipping Option



Enter Quantity:



This plasmid is compatible with all of the other DNA sequences available on this site, which are all sold in the same backbone. This flexibility allows you to create any vector you require, with a variety of functions, simply by compiling the relevant sections from our product range.

Vector: pSF-CMV-FMDV-Blast

Product Code: OG386

Quantity Provided:
 5µg

Size (bp):  5145

Bacterial Antibiotic Selection: Kanamycin

Origin and Compatibility: pUC high copy, derived from pBR322   

Copy Number: 500-700 copies per cell

Promoter: Cytomegalovirus (CMV) immediate early promoter.

Purpose: This vector allows the expression of two genes from one vector, where the second gene produced from the mRNA is the blasticidin antibiotic resistance gene (blast) under the control of the internal ribosome entry site (IRES) from Foot and Mouth Disease Virus (FMDV). Transcription is driven by the CMV promoter. There is a multiple cloning site immediately downstream of the CMV promoter which is then followed by the IRES element driving the blast gene. 

Quality Validation: This vector has been demonstrated to express reporter genes to high levels under the CMV promoter, and express blast to under the control of the downstream IRES. The level of expression of the second gene (blast) is significantly lower (approximately 30-40-fold) than the level of expression achieved from the CMV promoter using cap-dependent mechanism. However, the level of expression from the IRES under the CMV promoter in this vector is still higher than many other constitutive promoters, such as SV40, using cap-dependent translation mechanisms in a range of cell lines. The reporter genes under the CMV promoter were inserted into the NcoI site and XbaI site, with the start codon and stop codon residing within each of these sites, respectively. The blast resistance gene placed under the control of the IRES was inserted into the PciI site and the NheI site of pSF-CMV-FMDV-PciI, with the start codon residing within the PciI site. The blasticidin gene terminates upstream of the NheI site. Reporter gene expression and antibiotic resistance was validated in 293 cells. 

Quality Sequencing Analysis: This vector has been fully sequenced using primers F1-F10. The sequences and details of these primers are available through our website.

Intellectual Property Status: According to our IP-friendly policy, this plasmid is sold free of reach-through rights on any derivatives you may create.

Genetic Modifications to standard parts:

  • CMV promoter – An NcoI site has been ablated in the CMV promoter. This change does not reduce expression.
  • KanR cassette – This KanR resistance region is not a wild type sequence, it has been modified to remove all restriction sites that conflict with the SnapFastTM system and to retain a high level of antibiotic resistance. It has been validated in E.coli.  
  • Blasticidin resistance gene – The blast gene has been modified to remove StuI, BsgI and SacI sites. These changes did alter the amino acid sequence of the protein and do not effect resistance.  

Restriction site notes:

  • Bgl2, SwaI, and PmeI each cut the vector at two sites positioned to flank the promoter, origin, and KanR, respectively. KpnI cuts at three positions in this plasmid.
  • BsgI and BseRI recognise non-palindromic DNA sequences and cleave upstream of their recognition sites, within the stop codon that is found inside the XbaI restriction site.